ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0855

Addition of Immunosuppressive Agents And/or Intravenous Immunoglobulin to Steroids in the Treatment of Susac Syndrome: A National Cohort Study

Alexandra Kachaner1, Arthur Mageau1, Tiphaine Goulenok2, Chrystelle Francois2, Marie-Paule Chauveheid2, Thomas Papo1 and Karim Sacré1, 1Université Paris Cité, Paris, France, 2Assistance Publique Hôpitaux de Paris, Paris, France

Meeting: ACR Convergence 2024

Keywords: Miscellaneous Rheumatic and Inflammatory Diseases, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Susac syndrome (SuS) is an exceedingly rare microvasculopathy of the brain, retina and inner ear affecting young patients with potential lifelong sequelae. No randomized controlled trial has been published or declared as ongoing in SuS. We aimed to compare the efficacy of steroids given alone or associated with immunosuppressive (IS) agents and/or intravenous immunoglobulin (IVIg) for the prevention of relapse in SuS.

Methods: CarESS study is a prospective multicenter national cohort study that started in December 2011, including all consecutive patients with SuS. SuS was defined either by i) the triad of encephalopathy with typical brain MRI abnormalities, cochleo-vestibular damage and multiple occlusions of retinal central artery branches or ii) at least two of the three criteria without any alternative diagnosis. Collected data included fundoscopy, retinal angiography, audiometry, cerebrospinal fluid, brain MRI and treatment received. The primary outcome was the first relapse defined by new clinical symptoms or signs and new abnormalities on retinal angiography, audiometry or brain MRI leading to treatment intensification.

Results: Sixty-four SuS patients (mean (SD) age at diagnosis 35 (11) years; female ratio 64%) were included. Among them, 40 patients received steroids alone as a first-line therapy while 20 received steroids in combination with IS agents and/or IVIg. Overall, 46 (72%) patients experienced a first relapse with a median [95%CI] relapse-free survival time of 3.96 [2.24-16.07] months. Comparison of relapse-free survival demonstrated no significant difference between the two treatment strategies (HR [95%CI] = 1.11 [0.56-2.17], p=0.76). In patients who first relapsed while treated by steroids alone, there was no significant difference in second relapse-free survival between those who did or did not receive IS agents and/or IVIg as a second-line therapy (HR [95%CI] = 2.66 [0.63-11.18], p = 0.18).

Conclusion: Our findings did not support the systematic use of IS drugs in SuS to prevent relapse. Immunosuppressive drugs should be tested in a multicenter prospective randomized trial in SuS with the primary aim to prevent irreversible damage

Supporting image 1

Table 1 Patients characteristics at SuS onset
Qualitative variables are expressed as a number (percentage). IS, immunosuppressive; IVIg, intravenous immunoglobulin.; dB, decibels. Immunosuppressive drugs included cyclophosphamide (n=9), azathioprine (n=4) or mycophenolate mofetil (n=1)
*at start of treatment
** 4 patients received antiplatelets or anticoagulants only (i.e. without steroids nor IS/IVIg)

Supporting image 2

First relapse free survival according to treatment strategy
Kaplan-Meier curves of the survival without first relapse among patients who did (steroids + IS and/or IVIg) or did not (steroids) receive IS agents and/or IVIg.
P value was calculated with a Cox proportional hazard model. The model was adjusted on age, sex, center and presence of encephalopathy at diagnosis.
Patients who did not received either steroids, IS agents or IVIg at disease onset (n=4) were excluded from the analysis. The shaded areas refer to de 95% confidence bands. The “Cumulative Number of Censoring” refers to patients who were lost to follow-up.


Disclosures: A. Kachaner: None; A. Mageau: None; T. Goulenok: None; C. Francois: None; M. Chauveheid: None; T. Papo: None; K. Sacré: None.

To cite this abstract in AMA style:

Kachaner A, Mageau A, Goulenok T, Francois C, Chauveheid M, Papo T, Sacré K. Addition of Immunosuppressive Agents And/or Intravenous Immunoglobulin to Steroids in the Treatment of Susac Syndrome: A National Cohort Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/addition-of-immunosuppressive-agents-and-or-intravenous-immunoglobulin-to-steroids-in-the-treatment-of-susac-syndrome-a-national-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/addition-of-immunosuppressive-agents-and-or-intravenous-immunoglobulin-to-steroids-in-the-treatment-of-susac-syndrome-a-national-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology